10:00 am
Workshop A: Implementing AI & In Silico Technologies to De-Risk the Discovery of Induced Proximity Therapeutics & Accelerate Their Translation
1:00 pm
Workshop B: Enhancing Oral Bioavailability of Bivalent Degraders to Improve Patient Exposure & Maximise Therapeutic Efficacy
Zoran Rankovic
Director & Professor - Chemical Biology & Protein Degradation, Institute of Cancer Research
Andy Pike
Project leader, DMPK, Oncology R&D, AstraZeneca
Koichi Ito
Senior Director Biology, Prelude Therapeutics
3:00 pm
Afternoon Break & Networking
3:30 pm
Workshop C: From Hit to Lead – Navigating Key Checkpoints for Go/No-Go Decisions on Turning Your Initial Hits into Functional Induced Proximity Drugs
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok